

Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB

NCT07478484

Status	RECRUITING
Phase	Phase 4
Sponsor	Jing Zhou
Enrollment	144 participants

Key Eligibility Criteria

Inclusion (3)

- Patients diagnosed with complicated intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), complicated urinary tract infection (cUTI), or bloodstream infection (BSI);
- Patients with confirmed infections caused by metallo- β -lactamase-producing carbapenem-resistant Gram-negative bacteria (MBL-CR-GNB), as determined by genotypic testing using next-generation sequencing (NGS) or carbapenem resistance gene testing;
- Patients receiving treatment with ceftazidime-avibactam in combination with aztreonam.

Exclusion (5)

- Patients aged under 18 years;
- Patients with known hypersensitivity to ceftazidime, avibactam, aztreonam, or any of the excipients; or those with a history of severe hypersensitivity reactions (e.g., anaphylactic shock, severe skin reactions) to any other β -lactam antibacterial agents (such as penicillins, monobactams, or carbapenems);
- Pregnant or breastfeeding women;
- Patients unable to comprehend or comply with the study protocol;
- Any other condition which, in the investigator's discretion, makes the patient unsuitable for participation in the trial.

Locations (1 total)

Jing Zhou, Nanjin, Jiangsu, China